Ipragliflozin
This SGLT2 inhibitor works by blocking a kidney protein that reabsorbs glucose, causing excess sugar to be excreted in the urine and thereby lowering blood sugar levels in people with type 2 diabetes. It also promotes modest weight loss and blood pressure reduction.
Молекулярная масса
404,5000 g/mol
LogP
2,50
TPSA
118,00 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
2D Структура
Cite this structure
Embed this structure
SMILES
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
Molecular Formula
C21H21FO5S
HBD / HBA
4 / 7
Вращаемые Связи
4
Тяжёлые Атомы
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
This SGLT2 inhibitor works by blocking a kidney protein that reabsorbs glucose, causing excess sugar to be excreted in the urine and thereby lowering blood sugar levels in people with type 2 diabetes. It also promotes modest weight loss and blood pressure reduction.
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Yes, Ipragliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2018096. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10453870. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ipragliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ipragliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ipragliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ipragliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ipragliflozin"></drugfyi-drug>